Reoperative Surgical Aortic Valve Replacement Versus Transcatheter Valve-in-Valve Replacement for Degenerated Bioprosthetic Aortic Valves Julius I. Ejiofor, MD, Maroun Yammine, MD, Morgan T. Harloff, MD, Siobhan McGurk, BS, Jochen D. Muehlschlegel, MD, MMS, Prem S. Shekar, MD, Lawrence H. Cohn, MD, Pinak Shah, MD, Tsuyoshi Kaneko, MD The Annals of Thoracic Surgery Volume 102, Issue 5, Pages 1452-1458 (November 2016) DOI: 10.1016/j.athoracsur.2016.05.086 Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of inclusion and exclusion criteria used for patient selection. (AV = aortic valve; SAVR = surgical aortic valve replacement; STS = The Society for Thoracic Surgeons; TViV = transcatheter valve in valve replacement.) The Annals of Thoracic Surgery 2016 102, 1452-1458DOI: (10.1016/j.athoracsur.2016.05.086) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Kaplan-Meier survival curve for the 22 matched pairs by procedure type—surgical aortic valve replacement (SAVR [blue line]) and transcatheter valve in valve replacement (TViV [red line]) out to 3 years. The Annals of Thoracic Surgery 2016 102, 1452-1458DOI: (10.1016/j.athoracsur.2016.05.086) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions